Get the Stockscreener App
5.60
0.00%
0.02
Atossa Therapeutics Inc stock is traded at $5.60, with a volume of 21,773.
It is up +0.00% in the last 24 hours and up +8.35% over the past month.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
See More
Previous Close:
$5.58
Open:
$5.53
24h Volume:
21,773
Relative Volume:
0.20
Market Cap:
$48.01M
Revenue:
-
Net Income/Loss:
$-34.77M
P/E Ratio:
-1.692
EPS:
-3.3097
Net Cash Flow:
$-29.79M
1W Performance:
+5.68%
1M Performance:
+8.35%
6M Performance:
-54.33%
1Y Performance:
-55.25%
1-Day Range:
$5.49
$5.7894
1-Week Range:
$5.162
$6.18
52-Week Range:
$3.76
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
1448 NW MARKET STREET, SEATTLE, WA
Compare ATOS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
5.575 | 48.05M | 0 | -34.77M | -29.79M | -3.3097 |
VRTX
Vertex Pharmaceuticals Inc
|
424.60 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
717.55 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.98 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.20 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.11 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women - PR Newswire
Atossa Genetics stock surges after FDA rare disease designation By Investing.com - Investing.com South Africa
Atossa Genetics stock surges after FDA rare disease designation - Investing.com
Atossa Therapeutics (ATOS) Secures FDA Designation for Pediatric Treatment - GuruFocus
Atossa gets rare pediatric disease tag for endoxifen in MAS By Investing.com - Investing.com South Africa
FDA awards Atossa Therapeutics rare pediatric designation for Z-endoxifen milestone - Traders Union
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome - PR Newswire
ATOS Stock Price, Quote & Chart | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
ATOS Should I Buy - Intellectia AI
Atossa Therapeutics (ATOS) price target decreased by 47.43% to 23.46 - MSN
ATOS stock tumbles 32% — here’s what retail investors think of the reverse stock split - MSN
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update - Aktiellt
Atossa Therapeutics joins industry leaders at LSINW2026 to advance cell therapy innovation momentum - Traders Union
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $20 - Moomoo
ATOS Ownership | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
Atossa Therapeutics Resolves Endoxifen Patent Disputes, Clarifies Rights - TipRanks
Atossa Therapeutics reaches settlement in Endoxifen patent dispute By Investing.com - Investing.com South Africa
Atossa Therapeutics reaches settlement in Endoxifen patent dispute - Investing.com
Atossa Therapeutics (NASDAQ: ATOS) settles key Endoxifen patent fight - Stock Titan
Atossa Therapeutics (ATOS) price target decreased by 31.37% to 44.62 - MSN
Atossa Therapeutics advances endoxifen as new option for DMD management - Traders Union
ATOS: Ascendiant Capital Lowers Price Target Despite Maintaining 'Buy' Rating | ATOS Stock News - GuruFocus
Atossa Therapeutics, Inc. advances Z-endoxifen pipeline with key U.S. FDA designations into 2026 - Traders Union
Atossa Therapeutics: A 2026 Regulatory Milestone in Sight - AD HOC NEWS
ATOS Stock Eyes Fresh Highs Amid Strong Buying Pressure - Cổng thông tin điện tử Tỉnh Sơn La
Atossa Therapeutics Seeks Shareholder Approval for Further Stock Consolidation - AD HOC NEWS
Atossa (NASDAQ: ATOS) CEO Steven Quay granted 65,000 RSUs after reverse split - Stock Titan
Atossa Therapeutics announces issuance of U.S. patent - MSN
Atossa Therapeutics (ATOS) CFO receives 63,000 RSUs over 3 years - Stock Titan
[ARS] ATOSSA THERAPEUTICS, INC. SEC Filing - Stock Titan
[DEF 14A] ATOSSA THERAPEUTICS, INC. Definitive Proxy Statement - Stock Titan
NCCN event spotlights Atossa Therapeutics, Inc. breast cancer innovation - Traders Union
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits
Entry Recap: Is Atossa Therapeutics Inc a speculative investment2026 Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Risk Off: Is Atossa Therapeutics Inc stock heavily shorted2026 Market WrapUp & Accurate Entry/Exit Alerts - baoquankhu1.vn
ATOS Price Today: Atossa Therapeutics, Inc. Stock Price, Quote & Chart - MEXC
H.C. Wainwright raises Atossa Genetics price target to $25 from $7 - Investing.com
ATOS Receives Significant Price Target Increase from HC Wainwrig - GuruFocus
Atossa Therapeutics (ATOS) Sees Increased Price Target Following Stock Split - GuruFocus
Aug Weekly: Is Atossa Therapeutics Incs growth already priced in2026 Decliners & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Atossa Therapeutics Reports 2025 Financial Results and Advances (Z)-Endoxifen in Rare Diseases and Oncology - Minichart
Atossa Therapeutics 2025 Annual Report: (Z)-Endoxifen Clinical Development, Intellectual Property, and Regulatory Strategy - Minichart
Atossa Therapeutics (ATOS) Reports Wider-Than-Expected Loss - GuruFocus
Atossa Genetics Investors to Decide on Key Corporate Proposals - AD HOC NEWS
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):